Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.
about
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice.Use of bevacizumab as a first-line treatment for metastatic breast cancer.Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.Resveratrol promotes regression of renal carcinoma cells via a renin-angiotensin system suppression-dependent mechanism.Bevacizumab: a review of its use in advanced cancer.Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma.The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.Ten years of anti-vascular endothelial growth factor therapy.Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer.
P2860
Q30313895-66825381-5DA7-48A9-B89A-61C4C9E8465AQ34671886-BC6E9E22-845D-413A-915C-4ECD0624C83BQ35445151-A2AC15DC-1E32-40C3-B6CD-58C3C701EE3FQ37632167-5D8E4173-7F48-4785-9951-5750363A4B41Q37700988-870A000B-ACB0-4D1C-882E-7FB19A74422BQ38260176-40A9F72E-B736-4EC8-B1D0-CBCAD18879DCQ38546217-460554FB-A870-4C57-B298-5824BB7D3459Q38550459-EF99F428-00BB-42CA-A42C-6A836A613752Q46407140-C5B0A52D-E336-44B6-BBBD-CE5EE15E4157Q46721561-A6C4CECB-74D8-4CBD-8BB1-5C8F23D371AEQ50204127-FDD8943F-990B-4486-8177-E69610534EDAQ51460841-05F179C5-A25A-400B-B70A-CCD99F0C762D
P2860
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Genetic variability of VEGF pa ...... vacizumab to standard therapy.
@en
Genetic variability of VEGF pa ...... vacizumab to standard therapy.
@nl
type
label
Genetic variability of VEGF pa ...... vacizumab to standard therapy.
@en
Genetic variability of VEGF pa ...... vacizumab to standard therapy.
@nl
prefLabel
Genetic variability of VEGF pa ...... vacizumab to standard therapy.
@en
Genetic variability of VEGF pa ...... vacizumab to standard therapy.
@nl
P2093
P2860
P50
P1433
P1476
Genetic variability of VEGF pa ...... vacizumab to standard therapy.
@en
P2093
Aruna T Bansal
Celine Pallaud
David W Miles
Eric Van Cutsem
Natasha Leighl
Paul Delmar
Sanne de Haas
Stefan J Scherer
P2860
P2888
P304
P356
10.1007/S10456-014-9438-1
P577
2014-07-11T00:00:00Z